Absence of Carcinogenic Response to Multiwall Carbon Nanotubes in a 2-Year Bioassay in the Peritoneal Cavity of the Rat

Julie Muller, Monique Delos, Nadtha Panin, +3

Toxicological Sciences

Effect of a New Functional<i>CYP3A4</i>Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant Patients

Laure Elens, Ron HN van Schaik, Nadtha Panin, +5

Pharmacogenomics

Sintered Indium-Tin-Oxide (ITO) Particles: A New Pneumotoxic Entity

Dominique Lison, Julie Laloy, Ingrid Corazzari, +6

Toxicological Sciences

AsthmaEngineeringInflammatory Lung DiseaseImmunologyNanotoxicology +20

ABCB1 1199G&gt;A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines

Géraldine Dessilly, Laure Elens, Nadtha Panin, +4

PLoS ONE

<scp>IL</scp>‐1α induces <scp>CD11b^low</scp> alveolar macrophage proliferation and maturation during granuloma formation

François Huaux, Sandra Lo Re, Giordano Giulia, +13

The Journal of Pathology

Inflammatory Lung DiseaseLung InflammationInnate Immune SystemImmunologyImmune Regulation +22

Mesothelioma response to carbon nanotubes is associated with an early and selective accumulation of immunosuppressive monocytic cells

François Huaux, Virginie d’Ursel de Bousies, Marie-Astrid Parent, +12

Particle and Fibre Toxicology

Impact of ABCB1 1236C &gt; T-2677G &gt; T-3435C &gt; T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib

Géraldine Dessilly, Nadtha Panin, Laure Elens, +2

Scientific Reports

Functional defect caused by the 4544G&gt;A SNP in ABCC2

Laure Elens, Donatienne Tyteca, Nadtha Panin, +4

Pharmacogenetics and Genomics

Dysregulated Proinflammatory and Fibrogenic Phenotype of Fibroblasts in Cystic Fibrosis

François Huaux, Sabrina Noël, Barbara Dhooghe, +8

PLoS ONE

InflammationCytokineFibrosisAnti-inflammatoryInflammatory Lung Disease +11

<i>ABCB1</i> 1199G&gt;A Polymorphism (rs2229109) Affects the Transport of Imatinib, Nilotinib and Dasatinib

Géraldine Dessilly, Laure Elens, Nadtha Panin, +3

Pharmacogenomics